TARGATT Trademark

Trademark Overview


On Wednesday, July 31, 2024, a trademark application was filed for TARGATT with the United States Patent and Trademark Office. The USPTO has given the TARGATT trademark a serial number of 98674891. The federal status of this trademark filing is RESPONSE AFTER NON-FINAL ACTION - ENTERED as of Wednesday, June 4, 2025. This trademark is owned by Applied StemCell Inc.. The TARGATT trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

cell lines, namely, cells for medical or clinical use; iPSC master cell line being cells for medical or clinical use; HEK293 master cell line being cells for medical or clinical use; CHO master cell line being cells for medical or clinical use; knock-in kit comprising primarily of cells for medical or clinical use, and also including nuclease or nucleic acid encoding the nuclease designed for fast and site-specific knock-in gene editing and tagging in cells;

research and development in the pharmaceutical and biotechnology fields; master cell generation services, namely, research and development in the field of cells; platform as a services (PAAS) featuring editing genes for the development of large fragment knock-in cell lines, bioproduction, and cell library construction;
targatt

General Information


Serial Number98674891
Word MarkTARGATT
Filing DateWednesday, July 31, 2024
Status661 - RESPONSE AFTER NON-FINAL ACTION - ENTERED
Status DateWednesday, June 4, 2025
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Goods and Servicescell lines, namely, cells for medical or clinical use; iPSC master cell line being cells for medical or clinical use; HEK293 master cell line being cells for medical or clinical use; CHO master cell line being cells for medical or clinical use; knock-in kit comprising primarily of cells for medical or clinical use, and also including nuclease or nucleic acid encoding the nuclease designed for fast and site-specific knock-in gene editing and tagging in cells;
Pseudo MarkTARGET ATTP
Goods and Servicesresearch and development in the pharmaceutical and biotechnology fields; master cell generation services, namely, research and development in the field of cells; platform as a services (PAAS) featuring editing genes for the development of large fragment knock-in cell lines, bioproduction, and cell library construction;

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, June 3, 2025
Primary Code005
First Use Anywhere DateFriday, April 1, 2011
First Use In Commerce DateFriday, April 1, 2011

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateTuesday, June 3, 2025
Primary Code042
First Use Anywhere DateFriday, April 1, 2011
First Use In Commerce DateFriday, April 1, 2011

Trademark Owner History


Party NameApplied StemCell Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressMilpitas, CA 95035

Trademark Events


Event DateEvent Description
Wednesday, July 31, 2024NEW APPLICATION ENTERED
Tuesday, February 18, 2025NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, February 19, 2025ASSIGNED TO EXAMINER
Wednesday, March 5, 2025NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, March 5, 2025NON-FINAL ACTION E-MAILED
Wednesday, March 5, 2025NON-FINAL ACTION WRITTEN
Tuesday, June 3, 2025CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, June 3, 2025TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, June 4, 2025TEAS/EMAIL CORRESPONDENCE ENTERED